Nebivolol: An endothelium-friendly selective β 1- adrenoceptor blocker

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 1, 2012, Pages 16-21

  Gao, Yuansheng ^a   Vanhoutte, Paul M ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

blocker; chronic heart failure; hypertension; nitric oxide; reactive oxygen species

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SCAVENGER;

ANTIOXIDANT ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; ISOMER; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; BENZOPYRANS; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; HEART FAILURE; HUMANS; HYPERTENSION; MOLECULAR STRUCTURE; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VASODILATION;

EID: 84855358922     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182073e27     Document Type: Review

References (69)

1. De Cree J, Geukens H, Leempoels J, et al. Haemodynamic effects in man during exercise of a single oral dose of nebivolol (R 67555), a new beta-1-adrenoceptor blocking agent: a comparative study with atenolol, pindolol and propranolol. Drug Dev Res. 1986;8:109-117. (Pubitemid 16078129)
2. Pauwels PJ, Gommeren W, Van Lommen G, et al. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol. 1988;34:843-851. (Pubitemid 19014407)
3. Van de Water A, Janssens W, Van Nueten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol. 1988;11:552-563.
4. Van Bortel LM, de Hoon JN, Kool MJ, et al. Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol. 1997;51:379-384. (Pubitemid 27055905)
5. Gao Y, Nagao T, Bond RA, et al. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovascular Pharmacol. 1991;17:964-969.
6. Ignarro LJ. Different pharmacological properties of two enantiomers in a unique β-blocker, nebivolol. Cardiovasc Ther. 2008;26:115-134. (Pubitemid 351952828)
7. Bundkirchen A, Nguyen Q, Brixius K, et al. Lack of inverse agonistic activity of nebivolol, its D- and L-enantiomers and of in vivo metabolized nebivolol in human myocardium. Eur J Pharmacol. 2003;476:97-105. (Pubitemid 37315541)
8. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569. (Pubitemid 30080872)
9. Bordicchia M, Lorena S, Marcucci P, et al. Nebivolol induces lipolysis and uncoupling protein 1 expression in ex-vivo human visceral adipocytes [abstract]. Circulation. 2009;120:S530-S531.
10. Gosgnach W, Boixel C, Nevo N, et al. Nebivolol induces calcium independent signaling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol. 2001;38:191-199. (Pubitemid 32667145)
11. 3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol. 2003;42:232-236.
12. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198-1205. (Pubitemid 41216127)
13. Tran Quang T, Rozec B, Audigane L, et al. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta. Br J Pharmacol. 2009;156:601-608.
14. Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol. 1997;51:493-498. (Pubitemid 27317789)
15. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23-37. (Pubitemid 38161221)
16. Lefebvre J, Poirier L, Poirier P, et al. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol. 2007;63:575-582. (Pubitemid 46632567)
17. 1-blocker. J Clin Pharmacol. 2008;48:225-239.
18. Lindamood C, Ortiz S, Shaw A, et al. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol. 2010 [Epub ahead of print].
19. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
20. Dawes M, Brett SE, Chowienczyk PJ, et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460-463. (Pubitemid 29417735)
21. Parenti A, Filippi S, Amerini S, et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther. 2000;292:698-703. (Pubitemid 30067434)
22. 1-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide. 2002;7:75-82.
23. Maffei A, Vecchione C, Aretini A, et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens. 2006;19:579-586. (Pubitemid 43775847)
24. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:2747-2752. (Pubitemid 36667251)
25. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199-204. (Pubitemid 24282739)
26. Evangelista S, Garbin U, Pasini AF, et al. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res. 2007;55:303-309. (Pubitemid 46533933)
27. Mason RP, Kubant R, Jacob RF, et al. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol. 2006;48:862-869. (Pubitemid 44276465)
28. Georgescu A, Pluteanu F, Flonta ML, et al. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol. 2005;508:159-166. (Pubitemid 40169915)
29. 2-adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102:677-684.
30. Kou R, Michel T. Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling. J Biol Chem. 2007;282:32719-32729. (Pubitemid 350159316)
31. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol. 2003;23:615-621. (Pubitemid 36438074)
32. Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677-684. (Pubitemid 44843872)
33. Gao Y. The multiple actions of NO. Pflügers Archiv-Eur J Physiol. 2010;459:829-839.
34. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24:1023-1030. (Pubitemid 38737826)
35. Garbin U, Pasini AF, Stranieri C, et al. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res. 2007;56:515-521. (Pubitemid 350137774)
36. Sasser JM, Moningka NC, Cunningham MW Jr, et al. Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2010;298:R740-R746.
37. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251-1257.
38. Janssen PM, Zeitz O, Hasenfuss G. Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol. Eur J Pharmacol. 1999;366:223-232. (Pubitemid 29080786)
39. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795-3801. (Pubitemid 43739521)
40. Troost R, Schwedhelm E, Rojczyk S, et al. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol. 2000;50:377-379.
41. Flack JM, Ferdinand KC, Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens. 2003;5(suppl 1):5-11.
42. de Groot AA, Mathy MJ, van Zwieten PA, et al. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol. 2004;43:148-153.
43. Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol. 2003;42:1838-1844. (Pubitemid 37433667)
44. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007;25:731-741. (Pubitemid 46398866)
45. Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med. 2007;17:48-54. (Pubitemid 46205327)
46. Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol. 2009;53:379-387.
47. De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol. 2010;105:1433-1438.
48. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, doubleblind, crossover study. Circulation. 2001;104:511-514. (Pubitemid 32738117)
49. Georgescu A, Popov D, Dragan E, et al. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension. Eur J Pharmacol. 2007;570:149-158. (Pubitemid 47247683)
50. Vanhoutte PM, Shimokawa H, Tang EH, et al. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009;196:193-222.
51. Andre DE, Arnet U, Yang Z, et al. Nebivolol inhibits human aortic smooth muscle cell growth: effects of cell cycle regulatory proteins. J Cardiovasc Pharmacol. 2000;35:845-848. (Pubitemid 30327511)
52. Brehm BR,Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001;49:430-439. (Pubitemid 32119560)
53. Ignarro LJ, Sisodia M, Trinh K, et al. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide. 2002;7:83-90. (Pubitemid 35176999)
54. Falciani M, Rinaldi B, D'Agostino B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol. 2001;38:922-929. (Pubitemid 33104703)
55. Lacolley P, Challande P, Osborne-Pellegrin M, et al. Genetics and pathophysiology of arterial stiffness. Cardiovasc Res. 2009;81:637-648.
56. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663-667. (Pubitemid 351733365)
57. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004;44:305-310. (Pubitemid 39167227)
58. Javed U, Deedwania PC. b-Adrenergic blockers for chronic heart failure. Cardiol Rev. 2009;17:287-292.
59. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail. 2005;7:631-639. (Pubitemid 40732997)
60. FlatherM, Shibata M, Coats A, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-225. (Pubitemid 40222359)
61. Veverka A, L Salinas J. Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag. 2007;3:647-654. (Pubitemid 350104120)
62. Gunes Y, Tuncer M, Guntekin U, et al. Regional functions of the left ventricle in patients with coronary slow flow and the effects of nebivolol. Ther Adv Cardiovasc Dis. 2009;3:441-446.
63. Maffei A, Di Pardo A, Carangi R, et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension. 2007;50:652-656. (Pubitemid 47442727)
64. Seixas-Cambão M, Leite-Moreira AF. Pathophysiology of chronic heart failure. Rev Port Cardiol. 2009;28:439-471.
65. Baumhäkel M, Schlimmer N, Büyükafsar K, et al. Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice. J Pharmacol Exp Ther. 2008;325:818-823. (Pubitemid 351728031)
66. de Nigris F, Mancini FP, Balestrieri ML, et al. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric Oxide. 2008;19:57-63.
67. Toblli J, Cao G, Rivas C, et al. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hypertens. 2010;28:1007-1019.
68. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
69. Xhonneux R, Wouters L, Reneman RS, et al. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. Eur J Pharmacol. 1990;181:261-265. (Pubitemid 20185899)